Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.47 |
| ▸ | PPARA | Q07869 | 7/20 | 0.47 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.35 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.35 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10151761 | 0.88 | PPARG (0.48) | PPARGPPARASLC16A3SLC16A1MCTS1 | |
| SCHEMBL13994568 | 0.85 | PPARG (0.39) | PPARGPPARATMIGD3 | |
| SCHEMBL13994598 | 0.83 | PPARG (0.40) | PPARGPPARASLC16A3SLC16A1MCTS1 | |
| SCHEMBL13994496 | 0.83 | PPARG (0.39) | PPARGPPARASLC16A3SLC16A1MCTS1 | |
| SCHEMBL13994559 | 0.81 | PPARG (0.67) | PPARGPPARAGHSR | |
| SCHEMBL10151400 | 0.81 | PPARG (0.69) | PPARGPPARA | |
| SCHEMBL2972619 | 0.80 | TP53 (0.48) | PPARGPPARASLC16A3 | |
| SCHEMBL2972623 | 0.80 | TP53 (0.48) | PPARGPPARASLC16A3 | |
| SCHEMBL475127 | 0.79 | PPARG (0.56) | PPARGPPARAGHSR | |
| SCHEMBL475130 | 0.79 | PPARG (0.56) | PPARGPPARAGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1647546-B1 | NOVEL HETEROARYL DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | DANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | DANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | NR0B1, UGT1A10, NR0B2 | PPARG 282/4885PPARA 411/4885SLC16A3 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.